A novel Vascular Leak Index identifies sepsis patients with a higher risk for in-hospital death and fluid accumulation

Jay Chandra1†, Miguel A. Armengol de la Hoz2,3,4†, Gwendolyn Lee5,6, Alexandria Lee7, Patrick Thoral8, Paul Elbers8, Hyung-Chul Lee9, John S. Munger10, Leo Anthony Celi2,11,12 and David A. Kaufman10

Abstract

Purpose: Sepsis is a leading cause of morbidity and mortality worldwide and is characterized by vascular leak. Treatment for sepsis, specifically intravenous fluids, may worsen deterioration in the context of vascular leak. We therefore sought to quantify vascular leak in sepsis patients to guide fluid resuscitation.

Methods: We performed a retrospective cohort study of sepsis patients in four ICU databases in North America, Europe, and Asia. We developed an intuitive vascular leak index (VLI) and explored the relationship between VLI and in-hospital death and fluid balance using generalized additive models (GAM).

Results: Using a GAM, we found that increased VLI is associated with an increased risk of in-hospital death. Patients with a VLI in the highest quartile (Q4), across the four datasets, had a 1.61–2.31 times increased odds of dying in the hospital compared to patients with a VLI in the lowest quartile (Q1). VLI Q2 and Q3 were also associated with increased odds of dying. The relationship between VLI, treated as a continuous variable, and in-hospital death and fluid balance was statistically significant in the three datasets with large sample sizes. Specifically, we observed that as VLI increased, there was an increase in the risk for in-hospital death and 36–84 h fluid balance.

Conclusions: Our VLI identifies groups of patients who may be at higher risk for in-hospital death or for fluid accumulation. This relationship persisted in models developed to control for severity of illness and chronic comorbidities.

Keywords: Vascular leak, Septic shock, Hematocrit, Fluid resuscitation, Mortality, Fluid balance

Take home message

We created a novel vascular leak index (VLI) that identifies sepsis patients with higher risk for in-hospital death and fluid accumulation. Our VLI could be used to guide fluid resuscitation in sepsis patients.

Introduction

Sepsis is a leading cause of morbidity and mortality worldwide. In 2017, there were approximately 49 million sepsis cases worldwide, resulting in 11 million related deaths [1–5]. Sepsis is also costly, accounting for over $24 billion in annual hospital costs in the United States. Costs are also rising: One study found an increase of $1.5 billion to treat patients with hospital-associated sepsis over the three-year period from 2015 to 2018 [6].

Expert guidelines recommend infusion of intravenous (IV) fluids to increase venous return, cardiac stroke volume, cardiac output, and ultimately tissue perfusion [7]. Clinical studies, however, suggest that fewer than half...
of hemodynamically unstable patients respond to fluids when fluid response is defined as an increase in the cardiac output of more than 10% [8]. Even in patients whose cardiac output increases, IV fluids may be ineffective at improving tissue perfusion. Sepsis and other severe inflammatory states are often characterized by increased vascular permeability, termed the “vascular leak syndrome.” This results in physiologic derangements such as low circulating blood volume, impaired drug-binding capacity due to loss of plasma proteins, and organ failure due to tissue edema. Multiple studies associate a positive fluid balance with impaired organ function and a higher risk of death [9–11]. Expert guideline-recommended treatment of sepsis-induced hypotension includes administering IV fluids and vasopressors, either of which might be harmful to individual patients depending on the specific clinical situation [12, 13].

Measuring vascular leakage of fluid and protein requires special equipment that may not be widely available. Some investigators have proposed that the degree of vascular leak can be inferred by measuring hematocrit levels as IV fluids are infused. Hematocrit represents the concentration of hemoglobin, a protein too large to leak out of the vasculature. If infused fluid remains within the vasculature, hematocrit levels decline, as plasma volume increases and hemodilution occurs. If fluid leaks from the vasculature, the hematocrit should decline more slowly or even increase.

The goal of this investigation was to formulate an easily calculated vascular leak index (VLI) that clinicians can use to estimate prognosis and guide care. We hypothesized that increasing VLI would be associated with a more positive fluid balance and an increased risk for death. We aimed to refine existing definitions of VLI by factoring in other key characteristics and clinical measurements [14, 15]. We derived and validated a VLI by evaluating the hematocrit over time with respect to the volume of IV fluids infused.

**Methods**

**Study population**

We conducted a retrospective analysis of patients from the eICU, MIMIC-III, AmsterdamUMCdb, and SNUH databases [16–20]. Details on the patient cohort contained in each dataset are included in Additional file 1, and the relevant Institutional Review Board information for the de-identified data is at the end of the article.

Our study population includes patients diagnosed with sepsis by ICD9 and Angus criteria in the eICU-CRD and MIMIC-III databases [21]. In AmsterdamUMCdb, diagnosis of sepsis at admission, diagnosis of other severe infections, the use of antibiotics not for prophylaxis after surgery, and finally the presence of sepsis cultures were all used to identify sepsis patients. In the SNUH database, due to data constraints, we only used diagnosis of sepsis at admission to identify sepsis patients. We excluded patients who were diagnosed with bleeding by ICD9, had other excess fluid output (if the data were available), were undergoing renal replacement therapy, or received blood products. In addition, patients who were missing VLI-related data including fluid balance, height, weight, and hematocrit were excluded. In the eICU database, we only included patients in hospitals that we identified as having reliable fluid intake and output data.

**Vascular leak index**

We developed an intuitive equation for VLI based on relevant variables, including hematocrit levels at two time points during ICU care and net volume of fluid administered. We reasoned that the relationship between the volume of fluid infused and the change in hematocrit would yield information about how much fluid remained in or escaped from the vascular space. Specifically, the change in the hematocrit divided by the net fluid balance would quantify vascular leak. To normalize for differences among patients’ blood volume, we divided the fluid volume by each patient’s body surface area, as suggested by Nadler and colleagues (Eq. 1) [22]. We chose a multiplication factor of 1000 for easier interpretability. Only patients with positive fluid balance were included in the final patient cohort because they have an increased risk of death and severity of illness [23]. We reasoned that the group of patients with negative fluid balance represents a group who is not accumulating fluid and who is diuresing well. Thus, the clinical question of whether or not to give additional IV fluid to this group is less relevant. Finally, given the difficulty in recording fluid intake and output, we conducted median imputation for the lower and upper 5% quantiles of VLI.

**Vascular leak index**

\[
VLI = \left( \frac{Hct_{\text{final}} - Hct_{\text{initial}}}{\text{net fluid balance}} \right) \times \text{body surface area} \times 1000
\] (1)

**Variables and outcomes**

Initial hematocrit values were measured at study baseline (0 h), including the range during the previous 12 h when the patient may have been admitted to the emergency department through the following 18 h. The first hematocrit during this timeframe was considered the initial value. Final hematocrit levels were calculated as the average among hematocrit values measured between 18 and 36 h. The volume of total fluids administered between the previous 6 h prior to ICU admission and 36 h was recorded. Urine output was recorded, and the net fluid
balance was calculated as total fluid input minus urine output.

Patient outcomes included in-hospital death and fluid balance from 36 to 84 h after ICU admission, given the average ICU length of stay is 3.3 days or 79 h [24]. For the fluid balance outcome, we excluded patients who died within the 84 h period.

In addition to our variables of interest, we identified potential confounders that would account for a patients’ physical characteristics, such as age and sex. We accounted to disease severity and comorbidity burden with the Acute Physiology and Chronic Health Evaluation (APACHE) IV score and the Charlson Comorbidity Index (CCI) in eICU, the Oxford Acute Severity of Illness Score (OASIS) and the Elixhauser Comorbidity Score in MIMIC III, APACHE II in AmsterdamUMC, and APACHE II in SNUH. Comorbidity information was not available for the AmsterdamUMC and SNUH databases.

Data analysis
After developing our VLI, we trained a Generalized Additive Model (GAM) to determine the relationship between VLI and in-hospital death and 36–84 h fluid balance. We were interested in the nonlinear relationship between VLI and the two outcomes. Because of this, a spline term was introduced for VLI. In addition, we created quartiles of VLI as the explanatory variable.

In our models, we controlled for covariates, specifically severity of illness, chronic comorbidity (if available), age, and biological sex. The relationship between VLI and the outcome variables as determined by the GAM is visualized across all values of VLI, and the statistical significance of the relationship is determined by the ANOVA test.

All analyses were done in R 3.6.1. Code for our research can be found on our Github repository [23].

Results
Population description
In Table 1, we show how we derived our final patient cohort from our inclusion and exclusion criteria.

The demographics, clinical characteristics, and outcomes for the patients in the four databases are presented in Table 2 and Additional file 1: Table S1 for the fluid balance and in-hospital death outcomes, respectively. Covariates and outcomes stratified by VLI quartiles (for both the in-hospital death and fluid balance populations), in-hospital death, and fluid balance quartiles are presented in Additional file 1: Figs. S1–S4, respectively.

The final distribution of VLI for each database for the in-hospital death cohort is presented in Additional file 1: Fig. S5. VLI is left-skewed with a small number of patients having positive leak indices. A positive leak index indicates that a patient’s hematocrit increased over time despite the administration of fluids.

Association between VLI and in-hospital death
Using our GAM and analyzing VLI as quartiles, our results indicate that increasing VLI is associated with increased risk of in-hospital death in a dose-dependent manner. Patients in VLI Q4 had approximately 2.31 [CI 1.71–3.12], 1.61 [CI 1.26–2.05], and 2.13 [CI 1.42–3.20] increased odds of dying in the hospital compared to patients in VLI Q1 for eICU, MIMIC, and Amsterdam, respectively. VLI Q2 and Q3 were also associated with increased odds of dying (Additional file 1: Fig. S6).

Using our GAM and treating VLI as a continuous variable, we observe that in-hospital death changes with different values of VLI (Fig. 1). There is high variability in extreme low values of VLI. However, we observe relatively low variability in VLI from -7 to 2 in eICU. In this range, there is an increase in hospital death from approximately 10% to 25%. In MIMIC, from a VLI of -4 to 1, there is an increase in hospital death from approximately 14% to 23%. In Amsterdam, from a VLI of -3 to 1, there is an increase in hospital death from approximately 13% to 25%. Overall, changes in the smoothed VLI are significantly associated with changes in in-hospital death in eICU (p < 0.001), MIMIC (p = 0.004), and Amsterdam (p = 0.002).

See Additional file 1 for SNUH results (Additional file 1: Fig. S7 and Fig. S8).

Association between VLI and 36–84 h fluid balance
Using our GAM and treating VLI as a continuous variable, we observe that 36–84 h fluid balance changes with different values of VLI (Fig. 2). Again, there is high variability in extreme low values of VLI. From a VLI of -15 to a VLI of 2 in eICU, there is an increase in 36–84 h fluid balance from approximately 0 to 1500 ml. In MIMIC, from a VLI of -4 to 1, there is an increase in 36–84 h fluid balance from approximately 700 to 1600 ml. In Amsterdam, from a VLI of -4 to 1, there is an increase in 36–84 h fluid balance from approximately 1500 to 2200 ml. Overall, the smoothed VLI is significantly associated with changes in 36–84 h fluid balance in eICU (p < 0.001), MIMIC (p < 0.001), Amsterdam (p = 0.043).

Treating VLI as quartiles, we observe that patients in VLI Q4 had approximately 1131 ml (±158 ml, p < 0.001), 685 ml (±180 ml, p < 0.001), and 528 ml (±206 ml, p = 0.011) increased 36–84 h fluid balance compared to patients in VLI Q1 for eICU, MIMIC, and Amsterdam, respectively. Patients in VLI Q3 had approximately 800 ml (±158 ml, p < 0.001), 769 ml (±172 ml, p < 0.001), and 572 ml (±206 ml, p = 0.006) increased 36–84 h fluid balance from approximately 1500 to 2200 ml. Overall, the smoothed VLI is significantly associated with changes in 36–84 h fluid balance in eICU (p < 0.001), MIMIC (p < 0.001), Amsterdam (p = 0.043).

In our models, we controlled for covariates, specifically severity of illness, chronic comorbidity (if available), age, and biological sex. The relationship between VLI and the outcome variables as determined by the GAM is visualized across all values of VLI, and the statistical significance of the relationship is determined by the ANOVA test.

All analyses were done in R 3.6.1. Code for our research can be found on our Github repository [23].

Results
Population description
In Table 1, we show how we derived our final patient cohort from our inclusion and exclusion criteria.

The demographics, clinical characteristics, and outcomes for the patients in the four databases are presented in Table 2 and Additional file 1: Table S1 for the fluid balance and in-hospital death outcomes, respectively. Covariates and outcomes stratified by VLI quartiles (for both the in-hospital death and fluid balance populations), in-hospital death, and fluid balance quartiles are presented in Additional file 1: Figs. S1–S4, respectively.

The final distribution of VLI for each database for the in-hospital death cohort is presented in Additional file 1: Fig. S5. VLI is left-skewed with a small number of patients having positive leak indices. A positive leak index indicates that a patient’s hematocrit increased over time despite the administration of fluids.

Association between VLI and in-hospital death
Using our GAM and analyzing VLI as quartiles, our results indicate that increasing VLI is associated with increased risk of in-hospital death in a dose-dependent manner. Patients in VLI Q4 had approximately 2.31 [CI 1.71–3.12], 1.61 [CI 1.26–2.05], and 2.13 [CI 1.42–3.20] increased odds of dying in the hospital compared to patients in VLI Q1 for eICU, MIMIC, and Amsterdam, respectively. VLI Q2 and Q3 were also associated with increased odds of dying (Additional file 1: Fig. S6).

Using our GAM and treating VLI as a continuous variable, we observe that in-hospital death changes with different values of VLI (Fig. 1). There is high variability in extreme low values of VLI. However, we observe relatively low variability in VLI from -7 to 2 in eICU. In this range, there is an increase in hospital death from approximately 10% to 25%. In MIMIC, from a VLI of -4 to 1, there is an increase in hospital death from approximately 14% to 23%. In Amsterdam, from a VLI of -3 to 1, there is an increase in hospital death from approximately 13% to 25%. Overall, changes in the smoothed VLI are significantly associated with changes in in-hospital death in eICU (p < 0.001), MIMIC (p = 0.004), and Amsterdam (p = 0.002).

See Additional file 1 for SNUH results (Additional file 1: Fig. S7 and Fig. S8).

Association between VLI and 36–84 h fluid balance
Using our GAM and treating VLI as a continuous variable, we observe that 36–84 h fluid balance changes with different values of VLI (Fig. 2). Again, there is high variability in extreme low values of VLI. From a VLI of -15 to a VLI of 2 in eICU, there is an increase in 36–84 h fluid balance from approximately 0 to 1500 ml. In MIMIC, from a VLI of -4 to 1, there is an increase in 36–84 h fluid balance from approximately 700 to 1600 ml. In Amsterdam, from a VLI of -4 to 1, there is an increase in 36–84 h fluid balance from approximately 1500 to 2200 ml. Overall, the smoothed VLI is significantly associated with changes in 36–84 h fluid balance in eICU (p < 0.001), MIMIC (p < 0.001), Amsterdam (p = 0.043).

Treating VLI as quartiles, we observe that patients in VLI Q4 had approximately 1131 ml (±158 ml, p < 0.001), 685 ml (±180 ml, p < 0.001), and 528 ml (±206 ml, p = 0.011) increased 36–84 h fluid balance compared to patients in VLI Q1 for eICU, MIMIC, and Amsterdam, respectively. Patients in VLI Q3 had approximately 800 ml (±158 ml, p < 0.001), 769 ml (±172 ml, p < 0.001), and 572 ml (±206 ml, p = 0.006) increased 36–84 h fluid balance from approximately 1500 to 2200 ml. Overall, the smoothed VLI is significantly associated with changes in 36–84 h fluid balance in eICU (p < 0.001), MIMIC (p < 0.001), Amsterdam (p = 0.043).
fluid balance compared to patients in VLI Q1 for eICU, MIMIC, and Amsterdam, respectively.

See Additional file 1 for SNUH results (Additional file 1: Fig. S9).

**Discussion**

**Key findings**
We developed an equation to identify patients with increased vascular leak and found that a higher VLI was associated with a higher fluid balance between 36 and 84 h of ICU care and a higher risk of in-hospital death in patients with negative VLI. The results for the patients with positive VLI varied across the databases due to considerations that will be discussed in the limitations section. Our analyses were replicated in several datasets from North America, Europe, and Asia, suggesting that the relationships observed are robust.

Our results suggest a causal relationship between VLI and risk for death according to updated Bradford Hill rules [25]. We found a dose–response relationship between the quartiles of VLI and risk for death. Our observations are consistent across several databases from around the world, and they fit well with current models of biological plausibility with respect to the severity of vascular leak, organ dysfunction, fluid administration, and risk for death. Whether increased VLI is a marker or mediator of increased mortality still needs exploration. We believe it is likely to be both.

**Clinical implications**
Our findings suggest that clinicians may be able to determine whether a patient has high vascular leak within the

| Dataset (number of patient encounters) | Inclusion criteria: sepsis patients | Exclusion criteria | In-hospital death population | Fluid balance exclusion criteria | 36–84 h fluid balance population |
|----------------------------------------|------------------------------------|--------------------|------------------------------|---------------------------------|---------------------------------|
| eICU (200,859 patient encounters)     | 41,071                             | Diagnosis of bleeding or receiving blood products 2825 | 3246                          | Missing 36–84 h Fluid Balance Patient Mortality before 84 h 957 | 2206 |
|                                        |                                    | Excess Fluid Expulsion 3616 | RRT Patients 840 | Patients Under 16 and Erroneous Demographic Data 6 |                                   |
|                                        |                                    | Unreliable Fluid Data 9186 | Missing VLI Equation-related data 21,352 |                                   |                                   |
| MIMIC III (n = 53,423 patient encounters) | 18,764                             | Diagnosis of bleeding or receiving blood products 2690 | 4056                          | Missing 36–84 h Fluid Balance Patient Mortality before 84 h 391 | 3521 |
|                                        |                                    | Excess Fluid Expulsion 251 | RRT Patients 1777 | Patients Under 16 and Erroneous Demographic Data 820 |                                   |
|                                        |                                    | Unreliable Fluid Data 9170 | Missing VLI Equation-related data |                                   |                                   |
| AmsterdamUMC (n = 23,172 patient encounters) | 4363                              | Diagnosis of bleeding or receiving blood products 1295 | 1617                          | Missing 36–84 h Fluid Balance Patient Mortality before 84 h 237 | 1297 |
|                                        |                                    | Excess Fluid Expulsion 318 | RRT Patients 0 | Patients Under 16 and Erroneous Demographic Data 1133 |                                   |
|                                        |                                    | Unreliable Fluid Data | Missing VLI Equation-related data |                                   |                                   |
| SNUH (n = 16,082 patient encounters)   | 794                                | RRT Patients 541 | 146                           | Missing 36–84 h Fluid Balance Patient Mortality before 84 h 0 | 129 |
|                                        |                                    | Patients Under 16 and Erroneous Demographic Data 6 | Missing VLI Equation-related data 101 |                                   |                                   |

Table 1 Study population selection for all four databases
Table 2  Baseline characteristics for the 36–84 h fluid balance patient cohort in all four databases

|                  | eICU   | MIMIC III | Amsterdam | SNUH   |
|------------------|--------|-----------|-----------|--------|
|                  | n 2206 | n 3521    | n 1297    | n 129  |
| Age (mean (SD))  | 65.83 (16.09) | 65.65 (16.69) | Age (%) 18–39 | 166 (12.8) | Age (mean (SD)) 63.27 (15.69) |
| Gender = Male (%)| 1133 (51.4)  | 1897 (53.9) | 40–49 158 (12.2) | ICU type (%) Thoracic surgery ICU (RICU) 8 (6.2) |
| ICU Type (%)     | Cardiac ICU 132 (6.0) | Cardiac ICU (CICU) 426 (12.1) | 50–59 216 (16.7) | 180 (14.0) |
|                  | Cardiac ICU-Cardiothoracic ICU (CCU-CTICU) 145 (6.6) | 60–69 302 (23.3) | 180 (14.0)|
|                  | Cardiac surgery ICU (CSICU) 80 (3.6) | Cardiac surgery recovery unit (CSR) 450 (12.8) | 70–79 286 (22.1) | 180 (14.0) |
| Cardiothoracic ICU (CTICU) | 14 (0.6) | 80+ 169 (13.0) | 180 (14.0) |
| Medicine ICU (MICU) | 400 (18.1) | Medicine ICU (MICU) 1629 (46.3) | Gender = Male (%) 768 (59.2) | Medicine ICU (MICU) 81 (62.8) |
| Neuro ICU        | 20 (0.9) | 1297 (100.0) | 180 (14.0) |
| Med-Surg ICU     | 1288 (58.4) | Surgery ICU (SICU) 548 (15.6) | 180 (14.0) |
| Surgery ICU (SICU) | 127 (5.8) | Trauma Surgical ICU (TSICU) 468 (13.3) | 180 (14.0) |
| Weight (mean (SD)) | 81.07 (26.72) | Weight (mean (SD)) 87.34 (25.08) | Weight (mean (SD)) 77.75 (27.58) | Weight (mean (SD)) 59.62 (11.75) |
| Height (mean (SD)) | 168.37 (11.26) | Height (mean (SD)) 168.56 (10.66) | Height (mean (SD)) 173.28 (10.99) | Height (mean (SD)) 162.49 (8.36) |
| Body surface area (mean (SD)) | 1.93 (0.33) | Body Surface Area (mean (SD)) 2.00 (0.31) | Body surface area (mean (SD)) 1.92 (0.29) | Body surface area (mean (SD)) 1.63 (0.19) |
| Vascular leak index (median [IQR]) | -2.79 [-5.24, -1.46] | Vascular leak index (median [IQR]) -1.22 [-2.35, -0.35] | Vascular leak index (median [IQR]) -1.94 [-3.48, -0.79] | Vascular leak index (median [IQR]) -0.80 [-5.21, 1.13] |
| Apache IV Score (mean (SD)) | 73.74 (25.93) | Oasis Score (mean (SD)) 36.55 (8.29) | Apache II Score (mean (SD)) 21.18 (6.61) | Apache II Score (mean (SD)) 26.16 (8.90) |
| Charlson Comorbidity Index (mean (SD)) | 4.25 (2.88) | Elixhauser Comorbidity Score (mean (SD)) 10.60 (8.26) | 180 (14.0) |
| First hematocrit 18 h (mean (SD)) | 35.82 (6.82) | First hematocrit 18 h (mean (SD)) 33.44 (6.58) | First hematocrit 18 h (mean (SD)) 37 (7) | First hematocrit 18 h (mean (SD)) 30.43 (7.24) |
| Average hematocrit 18–36 h (mean (SD)) | 31.08 (5.49) | Average hematocrit 18–36 h (mean (SD)) 30.08 (4.32) | Average hematocrit 18–36 h (mean (SD)) 33 (6) | Average hematocrit 18–36 h (mean (SD)) 29.23 (4.86) |
| Hospital mortality (%) | 293 (13.3) | Hospital mortality (%) 529 (15.0) | Hospital mortality (%) 155 (12.0) | Hospital mortality (%) 24 (18.6) |
| Total fluid balance first 36 h (mean (SD)) | 3302.50 (3977.82) | Total fluid balance first 36 h (mean (SD)) 7049.42 (6213.95) | Total fluid balance first 36 h (mean (SD)) 4008.54 (2625.10) | Total fluid balance first 36 h (mean (SD)) 1524.30 (1440.73) |
| Total fluid balance 36–84 h (mean (SD)) | 768.82 (2676.75) | Total fluid balance 36–84 h (mean (SD)) 1375.12 (3647.28) | Total fluid balance 36–84 h (mean (SD)) 1973.01 (2626.22) | Total fluid balance 36–84 h (mean (SD)) 1026.19 (2192.98) |
First 36 h of ICU care and thus who may be less likely to benefit from or could even suffer harm from additional IV fluid. Knowing a patient’s VLI might guide treatment, as we might restrict further IV fluids in the setting of high vascular leak, as extravasation of fluid and a positive fluid balance are associated with impaired organ function and a higher risk of death [26].

Recent studies suggest that fluid-sparing sepsis resuscitation may lead to improved outcomes. The CENSER trial compared the early use of norepinephrine to fluid-based sepsis resuscitation, finding that shock control, fluid balance, and risk of cardiogenic pulmonary edema were lower with a fluid restrictive approach [27]. Richard et al. prospectively randomized patients to receive sepsis resuscitation guided by invasive measures of fluid responsiveness, finding that limiting fluids to patients who were responsive was associated with a lower fluid balance, a lower risk for death, and more ventilator-free days, though the latter two differences were not statistically significant [28]. The FRESH randomized controlled trial compared standard fluid resuscitation to IV fluid administration guided by a noninvasive fluid responsiveness monitor, finding that restricting IV fluids to patients who demonstrated fluid responsiveness was associated with lower fluid balance, lower risk for new renal replacement therapy, and lower risk for mechanical ventilation [29]. Our findings are consistent with and extend these observations, suggesting that patients with a higher VLI represent a population in whom IV fluids may be harmful, as they contribute to extravascular fluid accumulation. Our VLI does not require specialized equipment, which may make it attractive to care settings with limited resources.

A central goal of sepsis resuscitation is to restore or maintain blood flow to assure oxygen and metabolic substrate delivery to target tissues, supporting normal cellular function; this requires maintenance or restoration of the effective coordinated function of the macrocirculation, the microcirculation, and cellular function [30]. Increasing perfusion by augmenting cardiac output or arterial tone is crucial therapies. The fundamental goal of IV fluid is to increase venous return with the hope of increasing left ventricular end-diastolic volume, left ventricular stroke volume, cardiac output, and improvement of microcirculatory perfusion. However, a large proportion of critically ill patients do not demonstrate increases in cardiac output when they receive IV fluids [31].
Even in patients who demonstrate fluid responsiveness, IV fluids have only a small effect on blood volume and this effect may not be durable [32, 33]. Furthermore, even when IV fluids increase cardiac output, the increase may be offset by changes in other hemodynamic parameters, increasing oxygen delivery only slightly [34]. Because reduced endothelial barrier function and glycocalyx damage are characteristic of sepsis, a substantial proportion of infused fluids leaves the intravascular space within a short time [35, 36].

In situations like this, the harms of fluid may outweigh its benefits. Despite decades of research into identifying patients who are “fluid responsive,” clinicians still lack predictive tools that help identify patients who will benefit from IV fluids. The best metrics to understand whether fluid administration is likely to be helpful or harmful include dynamic indices of fluid response (stroke volume or cardiac output responses to fluid challenge, positive pressure ventilation, or a passive leg raise maneuver [37]) as well as indices of pulmonary vascular leakage (the volume of extravascular lung water or the pulmonary vascular permeability index [38]). Using these metrics often requires dedicated and often invasive monitoring devices. Our goal in this research was to develop a simple and intuitive index that uses widely available clinical data and might act as a surrogate measure for vascular leakage. The VLI we propose may identify patients who have increased risk of harm from IV fluids. We speculate that using VLI clinically could reduce harm associated with IV fluids. Further prospective studies are required to test this hypothesis formally. In addition, we hope future prospective studies will test whether using two hematocrit values taken at an earlier time point will provide validation that is more useful to guide care in the crucial first 24 h of ICU care.

We would also like to emphasize that we developed our VLI a priori based on physiological principles, not using regression models to identify variables that might contribute to risk. We used each independent data set to test whether there are associations between our VLI and the outcomes of interest. The fact that we saw similar associations in four independent data sets supports the generalizability of our findings despite creating models on each dataset separately.

**Limitations**

Limitations common to studies that use electronic medical record databases include mistakes in charting data that must be input manually. Errors in collecting fluid data are especially prevalent given the amount of different fluid inputs that a patient receives and the difficulty of accurately measuring urine output.
In addition, we found that most patients have a negative VLI. That is, the hematocrit decreased over time as they received IV fluids. In some patients, however, we observed an increase in hematocrit over the study period, even as the patients received IV fluids. Because we sought to exclude patients who received blood component transfusions, the reasons for the observed increase in hematocrit are uncertain. Due to the nature of our equation, patients with a rising hematocrit have the highest VLI and are classified in VLI Q4. The biological plausibility of placing these patients in the highest risk group is unclear. We believe that including patients with a rising hematocrit is one reason why we observe a high variability between VLI and the two outcomes of interest at high VLI values and why, in the AmsterdamUMC cohort, we observe decreasing mortality and decreasing 36–84 h fluid balance at the higher range of VLI.

Also, defining sepsis is particularly difficult, especially in a retrospective study when the diagnosis of sepsis may not be certain. In eICU, AmsterdamUMC, and MIMIC, we use relatively inclusive definitions, while in SNUH, we were restricted to identifying sepsis in patients who received that diagnosis at admission.

A further limitation is the nature of our intuitive equation. We reasoned from physiological principles and attempted to normalize by using the body surface area as a surrogate for circulating blood volume. We recognize that body surface area may be an unreliable surrogate [39]. Nevertheless, we sought an index that uses easily available data in order to facilitate bedside use, especially in low- or middle-income settings where more sophisticated monitoring may not be available. Future work should validate our VLI prospectively.

In the different hospitals that represent these four databases, fluid administration practices were quite different. In addition, depending on fluid administration practices, 36–84 h fluid balance and death can be significantly dependent on fluid balance in the first 36 h. This makes it difficult to cleanly describe the relationship between VLI and 36–84 h fluid balance.

Finally, while the patient population size was sufficiently large in the eICU, MIMIC, and AmsterdamUMC databases, the SNUH database had a very small final cohort size. The relationships seen in the other three datasets were generally maintained in the SNUH dataset, but the low sample size led to high variability in estimates.

Conclusion

Using a VLI derived from changes in hematocrit and net fluid balance within the first 36 h of a patient’s ICU care, we were able to estimate vascular leak and identify a population with a higher risk for dying and increased 36–84 h fluid balance in the hospital using a GAM that controlled for disease severity and chronic comorbidities. Future studies should validate our VLI and test whether using our VLI to guide therapy may result in patient-centered benefit. Other future studies should examine other outcomes, such as hospital length of stay, risk for new renal replacement therapy or mechanical ventilation, and others.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13054-022-03968-4.

Additional file 1 Supplementary Material.

Acknowledgements

The project was conceived, designed, and conducted during the 2019 fall course HST953 Collaborative Data Science in Medicine at the Harvard-MIT Division of Health Science and Technology. Yueh-Hsu, Runyu Hong, Shari B. Brosnanah, John S. Munger, David A. Kaufman, and Kimiko Huang supported this research during the 2019 NYU Health Datathon. LAC is funded by the National Institutes of Health through R01 EB017205. DAK is funded by the National Institutes of Health through 1UG3HL141722-01A1 and R01HL140362.

Author contributions

DAK, JAM, and LAC contributed to conceptualization; JC, MÁA, GL, and AL were involved in formal analysis and investigation; JC, MÁA, GL, AL, and DAK contributed to writing—original draft preparation; and DAK, LAC, PT, PE, and H-CL were involved in supervision. All authors contributed to methodology and writing—review and editing, and read and approved the final manuscript.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials

MIMIC III, eICU, and AmsterdamUMCdb are available to researchers through credentialed access. The SNUH dataset may be accessed by contacting the institution, receiving approval from the institution, and completing an IRB application for a proposed study.

Code availability

Our code is available at https://github.com/theonsesp/vol_leak_index.

Declarations

Ethics approval and consent to participate

The eICU study was exempt from institutional review board approval due to the retrospective design, lack of direct patient intervention, and the security schema, for which the re-identification risk was certified as meeting safe harbor standards by an independent privacy expert (Privacert, Cambridge, MA) (Health Insurance Portability and Accountability Act Certification no. 1031219-2). The data in MIMIC-III and MIMIC-CXR have been de-identified, and the institutional review boards of the Massachusetts Institute of Technology (No. 0403000206) and Beth Israel Deaconness Medical Center (2001-P-001699/14) both approved the use of the database for research. The Medical Research Ethics Committee of VU university medical center determined that the AmsterdamUMCdb study was exempt from their review and was not subject to the Dutch Medical Research Involving Human Subjects Act (WMO).

The process of developing AmsterdamUMCdb was audited by an external team led by a member of the privacy expert group at the Netherlands Federation of UMCS. The Ethics in Intensive Care Medicine group provided external ethics review and appraisal. The use of AmsterdamUMCdb is exempt from institutional review board approval due to a combination of de-identification,

Additional file 1 Supplementary Material.

Acknowledgements

The project was conceived, designed, and conducted during the 2019 fall course HST953 Collaborative Data Science in Medicine at the Harvard-MIT Division of Health Science and Technology. Yueh-Hsu, Runyu Hong, Shari B. Brosnanah, John S. Munger, David A. Kaufman, and Kimiko Huang supported this research during the 2019 NYU Health Datathon. LAC is funded by the National Institutes of Health through R01 EB017205. DAK is funded by the National Institutes of Health through 1UG3HL141722-01A1 and R01HL140362.

Author contributions

DAK, JAM, and LAC contributed to conceptualization; JC, MÁA, GL, and AL were involved in formal analysis and investigation; JC, MÁA, GL, AL, and DAK contributed to writing—original draft preparation; and DAK, LAC, PT, PE, and H-CL were involved in supervision. All authors contributed to methodology and writing—review and editing, and read and approved the final manuscript.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials

MIMIC III, eICU, and AmsterdamUMCdb are available to researchers through credentialed access. The SNUH dataset may be accessed by contacting the institution, receiving approval from the institution, and completing an IRB application for a proposed study.

Code availability

Our code is available at https://github.com/theonsesp/vol_leak_index.

Declarations

Ethics approval and consent to participate

The eICU study was exempt from institutional review board approval due to the retrospective design, lack of direct patient intervention, and the security schema, for which the re-identification risk was certified as meeting safe harbor standards by an independent privacy expert (Privacert, Cambridge, MA) (Health Insurance Portability and Accountability Act Certification no. 1031219-2). The data in MIMIC-III and MIMIC-CXR have been de-identified, and the institutional review boards of the Massachusetts Institute of Technology (No. 0403000206) and Beth Israel Deaconness Medical Center (2001-P-001699/14) both approved the use of the database for research. The Medical Research Ethics Committee of VU university medical center determined that the AmsterdamUMCdb study was exempt from their review and was not subject to the Dutch Medical Research Involving Human Subjects Act (WMO).

The process of developing AmsterdamUMCdb was audited by an external team led by a member of the privacy expert group at the Netherlands Federation of UMCS. The Ethics in Intensive Care Medicine group provided external ethics review and appraisal. The use of AmsterdamUMCdb is exempt from institutional review board approval due to a combination of de-identification,
contractual, and governance strategies where re-identification is not reasonably likely and can therefore be considered as anonymous information in the context of the General Data Protection Regulation (GDPR). The data in the SNUH dataset have been de-identified, and the institutional review boards of the Seoul National University Hospital have approved the use of this data for our research (SNUH 2106–118-1228).

Consent for publication
All authors have approved this manuscript for publication.

Competing interests
Dr. Leo A. Celi was funded by the NIH through NIBIB grant R01 EB017205. Dr. David A. Kaufman is funded by the National Institutes of Health through U1G3HL141722-01A1 and R01HL140362. Dr. Kaufman is a member of the Medical Advisory Board of Pulsion Medical Systems, has received grant support from Cheetah Medical, and serves as a consultant to FloSonic Medical.

Author details
1Harvard College, Harvard University, Cambridge, MA 02138, USA. 2Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA. 3Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 4Big Data Department, Fundación Progreso y Salud, Regional Ministry of Health of Andalucía, Sevilla, Spain. 5David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 6Harvard Kennedy School, Boston, MA, USA. 7Harvard T.H. Chan School of Public Health, Boston, MA, USA. 8Intensive Care Unit, Amsterdam University Medical Center, Amsterdam, The Netherlands. 9Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Korea. 10Division of Pulmonary, Critical Care and Sleep Medicine, NYU School of Medicine, New York, NY, USA. 11Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. 12Department of Bio-statistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Received: 25 December 2021 Accepted: 29 March 2022
Published online: 11 April 2022

References
1. CDC. Data and reports. Centers for Disease Control and Prevention (2019). https://www.cdc.gov/sepsis/datareports/index.html. Accessed 27 Sept 2019.
2. Reducing the global burden of sepsis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224944/. Accessed 23 July 2021.
3. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study—PubMed. https://pubmed.ncbi.nlm.nih.gov/31954465/. Accessed 23 July 2021.
4. Rhee C, et al. Prevalence, underlying causes, and preventability of sepsis-associated mortality in US acute care hospitals. JAMA Netw Open. 2019;2(2):e187571. https://doi.org/10.1001/jamanetworkopen.2018.7571.
5. Liu V, et al. Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA. 2014;312(1):90–2. https://doi.org/10.1001/jama.2014.5804.
6. Premier. Premier Inc: Analysis: hospital-associated sepsis decreased by 15%. … Premier, (2019). https://www.premierinc.com/newsroom/press-releases/premier-inc-analysis-hospital-associated-sepsis-decreased-by-15-from-2015-2018. Accessed 27 Sept 2019.
7. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012. https://insights-ovid-com.expord1.hu.harvard.edu/pubmed?pmid=23353941. Accessed 12 Dec 2019.
8. Mark PE, Monnet X, Teboul J-L. Hemodynamic parameters to guide fluid therapy. Ann Intensive Care. 2011;9.
9. Bagshaw SM, Brophy PD, Cruz D, Ronco C. Fluid balance as a biomarker: impact of fluid overload on outcome in critically ill patients with acute kidney injury. Crit Care. 2008;12(1):169. https://doi.org/10.1186/cc6948.
10. Malbrain MLNG, et al. Results from the international conference of experts on intra-abdominal hypertension and abdominal compartment syndrome. I. Definitions. Intensive Care Med. 2006;32(11):1722–32.
11. Schier RW. Fluid administration in critically ill patients with acute kidney injury. CJASN. 2010;5(4):733–9. https://doi.org/10.2215/CJN.00060110.
12. Van Valkinburgh D, McGuigan J. Inotropes and vasopressors. In StatPearls, Treasure Island (FL): StatPearls Publishing (2019). Accessed 14 Oct 2019. http://www.ncbi.nlm.nih.gov/books/NBK462411/.
13. Valverde A, Gianotti G, Roja-Garcia E, Hathaway A. Effects of high-volume, rapid-fluid therapy on cardiovascular function and hematological values during isoflurane-induced hypotension in healthy dogs. Can J Vet Res. 2012;76(2):99–108.
14. Malbrain MLNG, et al. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. Anaesthesia Intensive Ther. 2014;46(5):361–80. https://doi.org/10.5603/AIT.2014.0060.
15. Cordemans C, et al. Fluid management in critically ill patients: the role of extravascular lung water, abdominal hypertension, capillary leak, and fluid balance. Ann Intensive Care. 2012;2(Suppl 1):S1. https://doi.org/10.1186/2110-5820-2-51-S1.
16. Sharing ICU Patient Data Responsibly Under the Society of C…: Critical Care Medicine. https://journals.lww.com/ccmjournal/FullText/2021/06000/Sharing_ICU_Patient_Data_Responsibly_Under_the_16.aspx. Accessed 07 Aug 2021.
17. The future is bright for precision medicine in South Korea. Accessed 07 Aug 2021. https://www.nature.com/articles/d44247-019-00005-7.
18. Pollard TJ, Johnson AEW, Raffa JD, Celi LA, Mark RG, Badawi O. The eICU Collaborative Research Database, a freely available multi-center database for critical care research. Sci Data. 2018;5:180178. https://doi.org/10.1038/sdata.2018.178.
19. Johnson AEW, et al. MIMIC-II, a freely accessible critical care database. Sci Data. 2016;3(1):1–9. https://doi.org/10.1038/sdata.2016.35.
20. Johnson A, Pollard T, Mark R. The MIMIC III clinical database. 2015. physio.org. https://doi.org/10.10326/czxxw26.
21. Angus DC, et al. A framework for the development and interpretation of different sepsis definitions and clinical criteria. Crit Care Med. 2016;44(3):e113–21. https://doi.org/10.1097/CCM.0000000000001730.
22. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51(2):224–32.
23. theonesp, theonesp/cap_leak_index (2019). Accessed 12 Dec 2019. https://github.com/theonesp/cap_leak_index.
24. Hunter A, Johnson L, Courtaas A. Reduction of intensive care unit length of stay: the case of early mobilization. Health Care Manag (Frederick). 2014;33(2):128–35. https://doi.org/10.1097/HCM.0000000000000006.
25. Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. Emerg Themes Epidemiol. 2015. https://doi.org/10.1186/s12982-015-0037-4.
26. Huang AC-C, et al. Fluid balance correlates with clinical course of multiple organ dysfunction syndrome and mortality in patients with septic shock. PLoS ONE. 2019;14(12):e0225423. https://doi.org/10.1371/journal.pone.0225423.
27. Permpikul C, Tongyo S, Varasalit T, Trairongrakul T, Chakorn T, Udompantarak S. Early use of norepinephrine in septic shock resuscitation (CENSER). A randomized trial. Ann R Coll Phys Surg. 2019;16:199(9):1097–105. https://doi.org/10.1166/rcsp.201806-1034OC.
28. Richard J-C, et al. Preload dependence indices to titrate volume expansion during septic response in critically ill. Chest. 2015;195. https://doi.org/10.1378/chest.15-0343.
29. Douglas IS, et al. Fluid response evaluation in sepsis hypotension and shock: a randomized clinical trial. Chest. 2020;158(4):1451–45. https://doi.org/10.1016/j.chest.2020.04.025.
30. Martin GS, et al. Perioperative Quality Initiative (POQI) consensus statement on fundamental concepts in perioperative fluid management: fluid responsiveness and venous capacitance. Perioper Med (Lond). 2020;9:12. https://doi.org/10.1186/s13741-020-00142-8.
31. Michard F, Teboul J-L. Predicting fluid responsiveness in ICU patients: a critical analysis of the evidence. Chest. 2002;121(6):2000–8. https://doi.org/10.1378/chest.121.6.2000.
32. Nunes TSO, Ladeira RT, Bafi AT, de Azvedo LCP, Machado FR, Freitas FGR. Duration of hemodynamic effects of crystalloids in patients with circulatory shock after initial resuscitation. Ann Intensive Care. 2014;4:25. https://doi.org/10.1186/s13419-014-0005-5.
33. Ueyama H, He YL, Tanigami H, Mashimo T, Yoshiya I. Effects of crystalloid and colloid preload on blood volume in the parturient undergoing cesarean section (CENSER). A randomized trial. Am J Respir Crit Care Med. 2015;190(6):6000/ Sharing ICU Patient Data Responsibly Under the 16.aspx.
spinal anesthesia for elective Cesarean section. Anesthesiology. 1999;91(6):1571–6. https://doi.org/10.1097/00000542-199912000-00006.

34. Shah DM, Prichard MN, Newell JC, Karmody AM, Scovill WA, Powers SR. Increased cardiac output and oxygen transport after intraoperative isovolemic hemodilution. A study in patients with peripheral vascular disease. Arch Surg. 1980;115(5):597–600. https://doi.org/10.1001/archsurg.1980.01380050023006.

35. Sánchez M, et al. Comparison of fluid compartments and fluid responsiveness in septic and non-septic patients. Anaesth Intensive Care. 2011;39(6):1022–9. https://doi.org/10.1177/0310057X1103900607.

36. Bark BP, Öberg CM, Grande P-O. Plasma volume expansion by 0.9% NaCl during sepsis/systemic inflammatory response syndrome, after hemorrhage, and during a normal state. Shock. 2013;40(1):59–64. https://doi.org/10.1097/SHK.0b013e3182986a62.

37. Pinsky MR, et al. Functional hemodynamic monitoring. Crit Care Clin. 2015;31(1):89–111. https://doi.org/10.1016/j.ccc.2014.08.005.

38. Jozwiak M, Teboul JL, Monnet X. Extravascular lung water in critical care: recent advances and clinical applications. Ann Intensive Care. 2015;5(1):38. https://doi.org/10.1186/s13613-015-0081-9.

39. Feldschuh J, Katz S. The importance of correct norms in blood volume measurement. Am J Med Sci. 2007;334(1):41–6. https://doi.org/10.1097/MAJ.0b013e318063c707.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.